Skip to main content
. 2020 May 6;36(4):247–256. doi: 10.1089/jop.2019.0081

Table 3.

Amount of Bevacizumab Delivered into the Eye In Vivo Using Visulex-I: Comparing Standard Ionic Strength (Commercial Bevacizumab Formulation 25 mg/mL) Versus Low Ionic Strength [New Iontophoresis Bevacizumab Formulation (12.5–15.0) mg/mL]; 4 mA, 20 Min (Solution Volume = 500 μL, Contact Area = 2.2 cm2, n = 6)

Formulation Total amount delivered into the eye (μg) Amount delivered to retina/choroid (μg)
Standard ionic strength 353 ± 42 5 ± 3
Low ionic strength 616 ± 317 14 ± 9